SecBot SecBot
425 ·Filed Nov 2, 2026

SYBX

SYNLOGIC, INC.
NEUTRAL
Impact 3/10
Horizonmonths Processed14d 18h ago SEC0001193125-26-442767
Rule 425 M&A communications
Actionable Insight • Neutral

The executive hires signal Caldera is building a public-company-ready leadership team ahead of the merger close. Monitor the S-4 effectiveness and stockholder vote timelines for the next catalyst.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK AT ENTRY AT T+5
Entry
$0.5600
T+0 close · Nov 2, 2026 · via day close
Latest settled
0.00%
T+5 · $0.5600 · next T+20 in 14d
Vs SPY
−0.08%
α at T+5
Latest observation
+11.84%
T+10 · FF3 residual α
  1. T+0 · Nov 2 $0.5600entry
  2. T+1 · 14d ago 0.00%α −0.30% · $0.5600
  3. T+5 · 8d ago 0.00%α −0.08% · $0.5600
  4. T+10 · todayOpen
  5. T+20 · in 14d Pending
  6. T+60 · in 2mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Caldera Therapeutics, the private biotech merging with Synlogic (SYBX), announced the appointment of Michelle Doig as CFO and Lee Giguere as Chief Legal Officer. The press release also reiterates the planned all-stock merger and an upsized concurrent private placement expected to generate approximately $278 million in gross proceeds, with closing targeted by early 2027. The filing is a routine M&A communication that adds no new financial terms or changes to the deal structure.

Key Financial Metrics

Deal Type
merger

Key Facts

  • Caldera appointed Michelle Doig as CFO and Lee Giguere as Chief Legal Officer.
  • The merger between Synlogic and Caldera is an all-stock transaction with a newly formed company.
  • Concurrent private placement upsized to approximately $278 million in gross proceeds.
  • Combined company plans to trade on NYSE American under ticker CALD.
  • Closing expected by early 2027, subject to stockholder approvals and SEC effectiveness of the S-4 registration statement.

Financial Impact

Concurrent private placement of approximately $278 million in gross proceeds; no changes to merger consideration or deal value disclosed.

dilutioncash_proceeds

Risk Factors

  • Merger requires approval from stockholders of both Synlogic and Caldera.
  • Registration statement on Form S-4 has not yet been declared effective.
  • Customary closing conditions and regulatory approvals remain outstanding.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
425 Filing (Primary)0001193125-26-442767
Document: 0001193125-26-442767-index-headers.html0001193125-26-442767
Document: 0001193125-26-442767-index.html0001193125-26-442767
Document: 0001193125-26-442767.txt0001193125-26-442767

Track record

5 reports on SYBX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 5, 202611d ago 425 Neutral 4/10 Entry $0.5600 Now $1.10 +96.43% settles Feb 3
  2. Nov 2, 202614d ago 425 Neutral 3/10 Viewing Entry $0.5600 Now $1.10 +96.43% settles Jan 29
  3. Jul 29, 202615w ago 425 / 8-K Bearish 7/10 Entry $1.12 to $1.08 Now $1.10 +1.79% ▲ +3.57% +9.82% vs SPY
  4. May 18, 202626w ago 25-NSE Bearish 7/10 Entry $0.6600 to $1.21 Now $1.10 −66.67% ▼ −82.58% −77.72% vs SPY
  5. Apr 30, 202628w ago 10-K/A Neutral 2/10 Entry $0.6050 to $0.7150 Now $1.10 +81.82% ▲ +18.18% +15.11% vs SPY
Showing 5 of 5

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026